Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1689-1695

  Vahdat, Linda T ^a,b   Papadopoulos, Kyriakos ^a   Balmaceda, Casilda ^a   McGovern, Trish ^a   Dunleavy, Jane ^a   Kaufman, Elizabeth ^a   Fung, Blanche ^a   Garrett, Thomas ^a   Savage, David ^a   Tiersten, Amy ^a   Ayello, Janet ^a   Bagiella, Emilia ^a   Heitjan, Daniel ^a   Antman, Karen ^a   Hesdorffer, Charles ^a  

^a Univ Coll of Phys and Surgeons ^*  (United States)

^b Division of Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; PACLITAXEL; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC CELL; HUMAN; LIVER TOXICITY; METASTASIS; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SENSORY NEUROPATHY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; NEUTROPENIA; PACLITAXEL; THIOTEPA; TREATMENT OUTCOME;

EID: 15644369128     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Clark, G., Sledge, G. W., Osborne, C. K., and McGuire, W. L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J. Clin. Oncol., 5: 55-61, 1987.
2. Mick, R., Begg, C. B., Antman, K., Korzun, A. H., and Frei, E., III. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res. Treat., 13: 33-38, 1989.
3. Antman, K. H., Rowlings, P. A., Vaughn, W. P., Pelz, C. J., Fay, J. W., Fields, K. K., Freytes, C. O., Gale, R. P., Hillner, B. E., Holland, H. K., Kennedy, M. J., Klein, J. P., Lazarus, H. M., McCarthy, P. L., and Saez, R. High dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J. Clin. Oncol., 15: 1870-1879, 1997.
4. Greenberg, P., Hortobagyi, G., Smith, T., Ziegler, L., Frye, D., and Buzdar, A. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol., 14: 2197-2205, 1996.
5. Ayash, L. J., Elias, A., Schwartz, G., Wheeler, C., Ibrahim, J., Teicher, B. A., Reich, E., Warren, D., Lynch, C, Richardson, P., Schnipper, L., Frei III, E., and Antman, K. Double dose-intense chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J. Clin. Oncol., 14: 2984-2992, 1996.
6. Bezwoda, W., Seymour, L., and Dansey, R. High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J. Clin. Oncol., 13: 2483-2489, 1995.
7. Vahdat, L., and Antman, K. Autologous hematopoietic stem cell transplantation for breast cancer. In: K. Atkinson (ed.), Clinical Bone Marrow and Stem Cell Transplantation: A Reference Textbook. Cambridge, United Kingdom: Cambridge University Press, 1997.
8. McCloskey, D., and Davidson, N. Paclitaxel-induced programmed cell death in human breast cancer cells. Proc. Am. Assoc. Cancer Res., 6: 416, 1995.
9. Milas, L., Hunter, N. R., Kurdoglu, B., Mason, K. A., Meyn, R. E., Stephens, L. C., and Peters, L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol., 35: 297-303, 1995.
10. Stemmer, S. M., Cagnoni, P. J., Shpall, E. J., Bearman, S. I., Matthes, S., Dufton, C., Day, T., Taffs, S., Hami, L., Martinez, C., Purdy, M. H., Arron, J., and Jones R. High dose paclitaxel, cyclophosphamide and cisplatin with autologous hematopoietic progenitor cell support: a phase I trial. J. Clin. Oncol., 14: 1463-1472, 1996.
11. Papadopoulos, K. P., Ayello, J., Tugulea, S., Heitjan, D. E, Williams, C., Reiss, R., Vahdat, L. T., Suciu-Foca, N., Antman, K. H., and Hesdorffer, C. S. Harvest quality and factors affecting collection and engraftment of progenitor CD34+ cells in patients with breast cancer scheduled for high dose CTCb with chemotherapy and G-CSF mobilized peripheral blood progenitor cell support. J. Hematotherapy, 6: 61-68, 1997.
12. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
13. Kennedy, M. J., Vogelsang, G. B., Jones, R. J., Farmer, E. R., Hess, A. D., Altomonte, V., Huelskamp, A. M., and Davidson, N. E. Phase I trial of Interferon γ to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol., 12: 249-257, 1994.
14. Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F., and Ritz, J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79: 517-526, 1992.
15. deMagalhaes-Silverman, M., Donnenberg, A., Elde, E., Lembersky, B., Lister, J., Rybka, W., Whiteside, T., and Ball, E. Post-transplant immunotherapy in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 16: 95, 1997.
16. Dunphy, F. R., Spitzer, G., Buzdar, A. U., Hortobagyi, G. N., Horwitz, L. J., Yau, J. C., Spinolo, J. A., Jagannath, S., Holmes, F., Wallerstein, R. O., Bohannan, P. A., and Dicke, K. A. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J. Clin. Oncol., 8: 1207-1216, 1990.
17. Broun, E. R., Sledge, G. W., Ansari, R., Loesch, D., Hromas, R., Cornetta, K., Hedderman, A., Cunningham, I., and Einhorn, L. H. Two cycles of high dose chemotherapy with aulologous bone marrow rescue (ABMR) as initial treatment for stage IV breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 85, 1994.
18. Crown, J., Raptis, G., Vandal, L., Fennelly, D., Hamilton, N., Hudis, C., Gilewski, T., Seidman, A., Reich, L., and Norton, L. Rapid administration of sequential high dose cyclophosphamide, melphalan, thiotepa supported by filgrastim + peripheral blood progenitors in patients with metastatic breasl cancer: a novel and very active treatment strategy. Proc. Am. Soc. Clin. Oncol., 13: 110, 1994.
19. Bitran, J. D., Samuels, B., Klein, L., Hanauer, S., Johnson, L., Marinec, J., Harris, E., Kempler, J., and White W. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant., 17: 157-162, 1996.
20. Mehra, R., Browne, V., Rondon, G., Mirza, N., and Champlin, R. Phase I/II study of multiple course high dose CTC with PBSC infusion for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 16: 100, 1997.
21. Mayordomo, J. I., Yubero, A., Cajal, R., Alonso, M., Saenz, A., Escudero, P., Isla, D., Iniguez, C., Larrode, P., Garcia-Prats, M. D., and Tres, A. Phase I trial of high dose paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with autologous peripheral blood stem cell rescue. Proc. Am. Soc. Clin. Oncol., 16: 102, 1997.
22. Somlo, G., Doroshow, J. H., Synold, T., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan, R., Raschko, J., Forman, S. J., Shibata, S., Telef, M., and Yen, Y. High dose adriamycin, cyclophosphamide and paclitaxel for patients with high risk and responsive stage IV breast cancer. Proc. Am. Soc. Clin. Oncol., 16: 110, 1997.
23. Yubero, A., Mayordomo, J. I., Iniguez, C., Larrode, P., Gonzalez, P., Adelantado, S., Cajal, R., Alonso, M., Saenz, A., Escudero, P., Isla, D., Garcia-Prats, M. D., and Tres, A. Neurotoxicity of high-dose paclitaxel is reversible and related to prior neurotoxic chemotherapy. Proc. Am. Soc. Clin. Oncol., 16: 86, 1997.
24. Teicher, B., Holden, S., Eder, J., Brann, T., Jones, S., Frei, E., III. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res., 49: 6994-6998, 1989.